Cryptocurrencies: 6,003
Markets: 542
Marketcap: $ 405.93 B
24h Vol: $ 51.77 B
BTC Dominance: 62.01%

Global market data

Cryptocurrencies: 6,003
Markets: 542
Marketcap: $ 405.93 B
24h Vol: $ 51.77 B
BTC Dominance: 62.01%

[ZEROHEDGE] Eli Lilly Suspends COVID-19 Antibody Therapy Trial Over “Potential Safety Concern”

Zero Hedge

Eli Lilly Suspends COVID-19 Antibody Therapy Trial Over “Potential Safety Concern”

Tyler Durden

Tue, 10/13/2020 – 14:41

Barely a week after applying for emergency use approval from the FDA for one of its COVID-19 antibody therapeutics, it appears trials for one of Eli Lilly’s therapeutic drugs focused on the virus (Eli Lilly is working on more than just one) have been paused, according to an NYT report.

Per the NYT report, the government-sponsored clinical trial has been paused because of a “potential safety concern.” The report cited emails that government officials sent on Tuesday to researchers at testing sites, which the company confirmed. The trial was designed to test the benefits of the therapy on hundreds of people already infected with the virus. The company did not say how many volunteers were sick, or any details about their illness.

This comes after Johnson & Johnson confirmed that it had voluntarily paused its Phase 3 vaccine trials after a participant in the 60k person trial came down with an unusual and unspecified illness. An AstraZeneca trial in the US has still not restarted.

As we noted last night, convincing the public to trust the vaccines is critically important, according to a team of analysts at Goldman Sachs, who recently warned that convincing the public to accept the vaccine is an understated risk.

Stocks tumbled on the news.

Join our Telegram channels

Join our Telegram group ➡️ t.me/Liquidary

Follow us Twitter ➡️ twitter.com/liquidary

 

Find the full article here

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

Liquidary.com will use the information you provide on this form to be in touch with you and to provide updates and marketing. You can unsubscribe anytime.